The Effect of 3-Week Consumption of Soya Beverage Enriched With Plant Sterols on Serum LDL-C

NCT ID: NCT02881658

Last Updated: 2018-05-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

201 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2017-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a local, single-center, two-arm, randomized, double-blind, placebo-controlled clinical trial that examines the LDL-C-lowering effect of the consumption of a soya beverage enriched with plant sterol for 3 weeks. This study also examines if there is other health-benefits by consuming the plant sterols fortified soya beverage in terms of serum total triglyceride, total and HDL cholesterol, other cardiometabolic risk factors and musculoskeletal-related traits including handgrip strength, gait speed, peak expiratory flow rate, bio-impedance and body balance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiovascular disease (CVD) is the third commonest cause of deaths in Hong Kong and accounting for 14.4% of all deaths in 2012. Robust data attest the causal role of low-density lipoprotein cholesterol (LDL-C) in the development and progression of CVD. Reduction of LDL-C levels achieved by pharmacological agents in conjunction with diet change has been demonstrated to significantly reduce CVD morbidity and mortality. Moreover, it has been frequently reported that dietary incorporation of plant sterols/stanols could reduce blood LDL-C level in both healthy and dyslipidaemic individuals with great inter-individual variability of LDL-C response. Therefore, functional food enriched with plant sterols/stanols not only may provide additional LDL-C lowering benefit in dyslipidaemic patients as an adjunct to traditional pharmacologic therapy, but also play a role in primary prevention of CVD in the general population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Plant sterols-enriched soya beverage provided by Vitasoy

Daily consumption of 2g of plant sterols as provided by one pack of 250 ml of plant sterols-enriched soya beverage for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).

Group Type EXPERIMENTAL

Plant sterols-enriched soya beverage provided by Vitasoy

Intervention Type DIETARY_SUPPLEMENT

the study product is a 2g plant sterols-enriched in 250ml soya beverage

Soya beverage provided by Vitasoy

Daily consumption of one pack of 250 ml of soya beverage (without plant sterols) for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).

Group Type PLACEBO_COMPARATOR

Soya beverage provided by Vitasoy

Intervention Type DIETARY_SUPPLEMENT

the placebo product is a 250 ml soya beverage

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plant sterols-enriched soya beverage provided by Vitasoy

the study product is a 2g plant sterols-enriched in 250ml soya beverage

Intervention Type DIETARY_SUPPLEMENT

Soya beverage provided by Vitasoy

the placebo product is a 250 ml soya beverage

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Southern Chinese male or female ≥ 18 years;
* In good general health as evidenced by medical history;
* Have the ability to understand the requirements of the study, provide written informed consent, including consent for the use and disclose of research-related health information, and comply with the study data collection procedures. Provide signed and dated informed consent form

Exclusion Criteria

* Subject with familial hypercholesterolemia;
* On regular medication(s) which affect gastrointestinal functions and blood lipids level for the past 3 months, such as, but not limited to:

* Antibiotics of \>1 week duration
* GI related medications such as antacids
* Having blood lipid lowering medications such as statins, selective cholesterol absorption inhibitors (e.g. ezetimibe), fibrates, niacin, resins, omega- 3
* Heavy-smokers (more than 1 pack per day)
* Subject with heavy alcohol intake (\>40 g/day for men ; \>30 g/day for women) (32), or having history of alcohol abuse within 12 months prior to the study
* Subjects with taste aversion to placebo/intervention soya beverages
* Subject refusing to stop the consumption of plant sterols-enriched products if any during the study (other than the studied product) or having regular consumption of sterols/stanols cholesterol-lowering supplements/functional foods or other related products such as:

* Sterol/ Stanol - containing margarines, milk, yoghurt drink and soya beverages
* Sterol / Stanol supplements
* Fish oils \& omega-3 supplements
* Subject receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters
* Subject currently involved in a clinical trial or in an exclusion period following participation in another clinical trial
* Pregnancy or lactation
* Having soy allergy
* Being a vegan
* Being an athlete
* Concurrently participating in weight management or dietary program
* On diet pills, such as, but not limited to chitosan and dulcolax
* With history of sitosterolemia
* Having history of hypercholesterolemia, diabetes, thyroid disease, severe kidney diseases, cardiovascular diseases, chronic gastrointestinal disorders, cancers and AIDs ( acquired immune deficiency syndrome)
* Having history of malabsorption syndrome arising from diseases such as, but not limited to celiac disease, short bowel syndrome, cystic fibrosis, pancreatitis, diseases of gall-bladder, liver or pancreas, intestinal infection, injury, surgery and radiotherapy
* Taking over-the-counter Chinese medications or supplements with cholesterol/lipid lowering and related claims
* High blood cholesterol at screening \[Total cholesterol level ≥6.22mmol/L\]
* High LDL cholesterol \[LDL cholesterol level ≥4.15mmol/L\]
* High blood triglyceride at screening \[Triglyceride ≥3.39mmol/L\]
* Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Professor Bernard Cheung

Professor of Department of Medicine, HKU

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bernard Man Yung Cheung

Role: PRINCIPAL_INVESTIGATOR

Li Ka Shing Faculty of Medicine, The University of Hong Kong

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam

Hong Kong, , Hong Kong

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

References

Explore related publications, articles, or registry entries linked to this study.

Chau YP, Cheng YC, Sing CW, Tsoi MF, Cheng VK, Lee GK, Cheung CL, Cheung BMY. The lipid-lowering effect of once-daily soya drink fortified with phytosterols in normocholesterolaemic Chinese: a double-blind randomized controlled trial. Eur J Nutr. 2020 Sep;59(6):2739-2746. doi: 10.1007/s00394-019-02119-w. Epub 2019 Oct 23.

Reference Type DERIVED
PMID: 31642984 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTC1521

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.